Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
AACR 2022
Join us for our Advances in Lower & Upper #GICancer: Highlights Webinars by VJOncology š£ š»
Featuring presentations & expert discussions on the latest breakthroughs and clinical developments in #upperGIcancers, with a focus on data and updates from recent internationalā¦ https://twitter.com/i/web/status/2017167200348422185
How should women with a BRCA1 mutation without breast cancer be managed? š§ š¬
Halle Moore (@HalleMooreMD, @ClevelandClinic) breaks down surveillance vs preventive surgeryāand why fertility plans & patient preferences must guide decisions.
Watch: ā¦ https://twitter.com/i/web/status/2017145872098754623
Managing cancer risk in BRCA1 mutation carriers without prior breast cancer
Halle Moore, MD, Cleveland Clinic, Cleveland, OH, comments on management options for women with a known BRCA1 mutati...
ow.ly
Ryan Sullivan at #ESMO25 explores individualized neoantigen therapies & vaccines in #Melanoma šÆ These approaches may boost efficacy without raising autoimmune toxicity, unlike combined checkpoint blockade regimens ā”š
Watch the insights š„
#melsmā¦ https://twitter.com/i/web/status/2016934651206484000
What are the benefits of integrating cancer vaccines into clinical practice?
Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, discusses the potential benefits of individualized neoantig...
ow.ly
Comparing #ADCs in #BreastCancer isnāt easy, as data are limited. FranƧois Poumeaud explains why switching targets or payloads may unlock added benefit, and why reliance on TOP1 inhibitors is a current bottleneck. More flexibility ahead?
Watch: ā¦ https://twitter.com/i/web/status/2016783499169014217
Challenges and future directions of ADC targets and payloads in breast cancer
Francois Poumeaud, MD, Oncopole Claudius Regaud, Toulouse, France, comments on the challenges of comparing different ant...
ow.ly
How do we define the right strategy for neuroendocrine carcinomas? š¤š¬
Juan Manuel OāConnor (@Juanmaoconnor) highlights the need for clear control arms to guide adjuvant vs neoadjuvant decisions, and tailoring surgery to tumor origin & patient context.
Watch for insights šā¦
Optimizing treatment strategies for neuroendocrine carcinomas
Juan Manuel O'Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, comments on the challenges of det...
twitter.com
AACR 2022
Join us for our Advances in Lower & Upper #GICancer: Highlights Webinars by VJOncology š£ š»
Featuring presentations & expert discussions on the latest breakthroughs and clinical developments in #upperGIcancers, with a focus on data and updates from recent internationalā¦ https://twitter.com/i/web/status/2017167200348422185
How should women with a BRCA1 mutation without breast cancer be managed? š§ š¬
Halle Moore (@HalleMooreMD, @ClevelandClinic) breaks down surveillance vs preventive surgeryāand why fertility plans & patient preferences must guide decisions.
Watch: ā¦ https://twitter.com/i/web/status/2017145872098754623
Managing cancer risk in BRCA1 mutation carriers without prior breast cancer
Halle Moore, MD, Cleveland Clinic, Cleveland, OH, comments on management options for women with a known BRCA1 mutati...
ow.ly
Ryan Sullivan at #ESMO25 explores individualized neoantigen therapies & vaccines in #Melanoma šÆ These approaches may boost efficacy without raising autoimmune toxicity, unlike combined checkpoint blockade regimens ā”š
Watch the insights š„
#melsmā¦ https://twitter.com/i/web/status/2016934651206484000
What are the benefits of integrating cancer vaccines into clinical practice?
Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, discusses the potential benefits of individualized neoantig...
ow.ly
Comparing #ADCs in #BreastCancer isnāt easy, as data are limited. FranƧois Poumeaud explains why switching targets or payloads may unlock added benefit, and why reliance on TOP1 inhibitors is a current bottleneck. More flexibility ahead?
Watch: ā¦ https://twitter.com/i/web/status/2016783499169014217
Challenges and future directions of ADC targets and payloads in breast cancer
Francois Poumeaud, MD, Oncopole Claudius Regaud, Toulouse, France, comments on the challenges of comparing different ant...
ow.ly
How do we define the right strategy for neuroendocrine carcinomas? š¤š¬
Juan Manuel OāConnor (@Juanmaoconnor) highlights the need for clear control arms to guide adjuvant vs neoadjuvant decisions, and tailoring surgery to tumor origin & patient context.
Watch for insights šā¦
Optimizing treatment strategies for neuroendocrine carcinomas
Juan Manuel O'Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, comments on the challenges of det...
twitter.com
